<DOC>
	<DOCNO>NCT01000896</DOCNO>
	<brief_summary>The primary purpose study explore safety tolerability AZD0530 combination carboplatin paclitaxel Japanese patient non small cell lung cancer epithelial ovarian cancer .</brief_summary>
	<brief_title>Study Assess Safety Tolerability AZD0530 Combination With Carboplatin Paclitaxel</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Saracatinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Japanese patient non small cell lung cancer epithelial ovarian cancer Must suitable treatment carboplatin paclitaxel Relatively good overall health cancer Poor bone marrow function ( produce enough blood cell ) . Poor liver kidney function . Patients unable discontinue drug know potent inhibitor inducer CYP3A4 within 2 week prior registration</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Phase I</keyword>
	<keyword>cancer</keyword>
	<keyword>solid tumor</keyword>
	<keyword>advanced solid malignancy</keyword>
	<keyword>NSCLC</keyword>
	<keyword>epithelial ovarian cancer</keyword>
	<keyword>dose escalation</keyword>
	<keyword>combination treatment</keyword>
	<keyword>src inhibitor</keyword>
	<keyword>Japanese</keyword>
</DOC>